Combination therapy shows response in relapsed leukemia

When leukemia returns or resists treatment, options are limited and the stakes are high. This review combined data from many studies on adults with relapsed or refractory acute myeloid leukemia. It looked at using two drugs together: hypomethylating agents and venetoclax. The main finding was that about half of patients saw their cancer respond. Specifically, the overall response rate was 50%, and 43% achieved a complete remission or a similar deep response. About 42% had no measurable residual disease left. The median overall survival was 8 months, and 40% were alive after one year. The analysis included 2,289 patients. Safety signals included serious infections, febrile neutropenia, and low blood cell counts. A key caveat is the high statistical heterogeneity, meaning the studies varied a lot, so the results should be interpreted with some caution. This combination may be a potential re-induction regimen for these patients, but it was not compared to more intensive salvage regimens.